These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27905011)

  • 21. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
    Souliotis K; Golna C; Kani C; Litsa P
    J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearance of psoriasis: the impact of private versus public insurance.
    Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
    Christophers E; Segaert S; Milligan G; Molta CT; Boggs R
    J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis.
    Svedbom A; Dalén J; Mamolo C; Cappelleri JC; Petersson IF; Ståhle M
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):215-223. PubMed ID: 24813476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
    Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
    J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
    Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
    Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER).
    Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M
    J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study.
    Sticherling M; McPherson T; de Lucas Laguna R; Costanzo A; Reed C; Artime E; Robert C; Lucas J; Schuster C; Mahé E
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1793-1808. PubMed ID: 35797001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Phototherapy Guidelines for Psoriasis: A Critical Appraisal and Comprehensive Review.
    Vassantachart JM; Soleymani T; Wu JJ
    J Drugs Dermatol; 2016 Aug; 15(8):995-1000. PubMed ID: 27538001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A description of treatment patterns of psoriasis by medical providers and disease severity in US women.
    Tajalli M; Li T; Drucker AM; Qureshi AA; Cho E
    J Psoriasis Psoriatic Arthritis; 2021 Jan; 6(1):45-51. PubMed ID: 33738385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
    J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary management of moderate to severe plaque psoriasis.
    Wu JJ
    Am J Manag Care; 2017 Dec; 23(21 Suppl):S403-S416. PubMed ID: 29297664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database.
    Noe MH; Shin DB; Doshi JA; Margolis DJ; Gelfand JM
    J Drugs Dermatol; 2019 Aug; 18(8):745-750. PubMed ID: 31424706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review.
    Abdelnabi M; Patel A; Rengifo-Pardo M; Ehrlich A
    Am J Clin Dermatol; 2016 Aug; 17(4):421-4. PubMed ID: 27283586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
    Sekhon S; Jeon C; Nakamura M; Yan D; Afifi L; Bhutani T; Levin E
    Psoriasis (Auckl); 2017; 7():65-72. PubMed ID: 29387609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.